Mortality Risk for Docetaxel-Treated, High-Grade Prostate Cancer With Low PSA Levels: A Meta-Analysis.

ABSTRACT:

Importance

Patients with high-grade prostate cancer with low levels of prostate-specific antigen (PSA; <4 ng/mL) are at high risk of mortality, necessitating an improved treatment paradigm.

Objective

To assess for these patients whether adding docetaxel to standard of care (SOC) treatment is associated with decreased prostate cancer-specific mortality (PCSM) and all-cause mortality (ACM).

Data sources

PubMed search from 2000 to 2022.

Study selection

Five prospective randomized clinical trials (RCTs) performed in the US, France, and the United Kingdom evaluating SOC treatment with radiotherapy and androgen deprivation therapy (ADT) or with radical prostatectomy vs SOC plus docetaxel.

Data extraction and synthesis

Individual data were included from patient

SUBMITTER: Mahal BA 

PROVIDER: S-EPMC10620614 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature